Investors are ecstatic about Dendreon's (Nasdaq: DNDN) win last week. Shares jumped 35% last week after the mid-Thursday approval announcement.

I'm in the "that's great, but …" camp. It's time to move on to other news. Two drugs also received late-week decisions from the Food and Drug Administration, and another is scheduled to hear this week.

On Friday, the FDA approved Vimovo, an arthritis drug from Pozen (Nasdaq: POZN) and AstraZeneca (NYSE: AZN). Pozen is trading flat on the news, but it's up 72% year to date, so there's probably a bit of selling on the news.

Vimovo is a combination of painkiller naproxen and AstraZeneca's heartburn drug Nexium. Non-steroidal anti-inflammatory drugs (NSAIDs) -- such as Advil and Celbrex from Pfizer (NYSE: PFE), and naproxen, the active ingredient in Bayer's Aleve -- can be hard on the stomach. Nexium is there to counteract that side effect.

Vimovo won't be in the same class of sales as Dendreon's Provenge; the latter should have no problem hitting blockbuster status, while Vimovo might be lucky to get $300 million in sales, according to one analyst. But with a market cap that's less than one-twentieth the size of Dendreon, Pozen doesn't exactly need sales to be that high.

Bristol-Myers Squibb (NYSE: BMY) also got a decision from the FDA, but it wasn't the positive kind. The agency wants three-year data from clinical trials investigating belatacept, which helps avoid rejection of transplanted kidneys. Investors knew the agency had some concerns over the two-year safety data that supported the application, but I figured the 13-to-5 vote by the advisory panel recommending approval would have been enough to sway the agency's reviewers. Guess not.

Looking ahead, tomorrow is InterMune's (Nasdaq: ITMN) PDUFA date for pirfenidone, which treats idiopathic pulmonary fibrosis (IPF). The FDA isn't bound by that date -- it could come early, as in Dendreon's case, but I wouldn't be surprised by a delay given the complexity of the case. Pirfenidone, which will go by the trade name Esbriet, only passed one of its two phase 3 trials, but it treats a disease that currently doesn't have any good treatment options.

Given the amount of uncertainty over what the FDA will do about pirfenidone, I expect InterMune's shares price could increase a lot more than Dendreon's 35% jump after the decision is handed down.

You're likely to hear a lot more about Dendreon in the coming months: its first treated patient, updates on its new manufacturing plant, potential suitors, and the list goes on. Read the press releases and articles, especially if you're a shareholder. Just don't forget that there's plenty of money to be made in biotech outside of Dendreon, too.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a recommendation of the Inside Value newsletter. The Fool has a disclosure policy.